A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data
for the PADOVA Investigators and Prasinezumab Study Group
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data'. Together they form a unique fingerprint.